Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Veure altres versions (1)

BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the treatment of RA with...

Descripció completa

Dades bibliogràfiques
Autors principals:	Ruiz Garcia, V, Jobanputra, P, Burls, A, Cabello, J, Vela Casasempere, P, Bort-Marti, S, Kynaston-Pearson, F
Format:	Journal article
Idioma:	English
Publicat:	2014

Ítems similars

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
per: Ruiz Garcia, V, et al.
Publicat: (2011)

Certolizumab pegol in therapy for rheumatoid arthritis
per: Galina Viktorovna Lukina, et al.
Publicat: (2012-06-01)

Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
per: M Connock, et al.
Publicat: (2010-10-01)

QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
per: Vera Nikolayevna Amirdjanova, et al.
Publicat: (2012-10-01)

New aspects of the pharmacotherapy of rheumatoid arthritis: a focus on certolizumab pegol
per: Evgeniy L'vovich Nasonov, et al.
Publicat: (2011-02-01)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
per: Emna Hannech, et al.
Publicat: (2021-06-01)

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol
per: Dmitry Evgenyevich Karateev, et al.
Publicat: (2012-04-01)

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
per: T. V. Korotaeva, et al.
Publicat: (2015-10-01)

Certolizumab pegol – new option in the treatment of psoriatic arthritis
per: Maria Majdan, et al.
Publicat: (2014-07-01)

Certolizumab pegol in the treatment of spondyloarthritis
per: Mariusz Korkosz
Publicat: (2014-09-01)

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
per: Smolen, JS, et al.
Publicat: (2024)

COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
per: Purcaru, O, et al.
Publicat: (2010)

Prefilled certolizumab pegol (Cimzia&reg;) syringes for self-use in the treatment of rheumatoid arthritis
per: J Rosa, et al.
Publicat: (2010-08-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
per: Sh. F. Erdes
Publicat: (2016-02-01)

Eosinophilic Annular Erythema Due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine
per: Andrea Bassi, et al.
Publicat: (2023-04-01)

The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports
per: José Alexandre Mendonça, et al.
Publicat: (2019-02-01)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
per: Stéphane Paul, et al.
Publicat: (2020-07-01)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
per: Mehmet Baysal, et al.
Publicat: (2018-09-01)

Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol
per: Lindsey J. Wanberg, et al.
Publicat: (2024-06-01)

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials
per: Tanaka, Y, et al.
Publicat: (2023)

Experience with long-term use of certolizumab pegol (Cimzia)
per: Karine Arnoldovna Lytkina, et al.
Publicat: (2013-10-01)

Experience with long-term use of certolizumab pegol (Cimzia)
per: Karine Arnoldovna Lytkina, et al.
Publicat: (2013-10-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population.
per: Ian R White, et al.
Publicat: (2022-01-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population
per: Ian R. White, et al.
Publicat: (2022-01-01)

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
per: Vivian P. Bykerk, et al.
Publicat: (2023-02-01)

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
per: Glatt, S, et al.
Publicat: (2019)

Quantitation of certolizumab pegol by validated liquid chromatography methods
per: Clóvis Dervil Appratto Cardoso Júnior, et al.
Publicat: (2023-11-01)

Certolizumab pegol in treatment of Crohn's disease with perianal lesions
per: I.L. Khalif, et al.
Publicat: (2018-04-01)

Active axial spondyloarthritis: potential role of certolizumab pegol
per: Ranatunga S, et al.
Publicat: (2014-02-01)

Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów
per: Piotr Wiland, et al.
Publicat: (2011-08-01)

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
per: Acosta-Felquer ML, et al.
Publicat: (2016-03-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS
per: P. I. Novikov, et al.
Publicat: (2018-07-01)

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol.
per: Hazes, J, et al.
Publicat: (2010)

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
per: A. Spadaro, et al.
Publicat: (2013-07-01)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease
per: Wojciech Blonski, et al.
Publicat: (2012-04-01)

Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
per: O V Knyazev, et al.
Publicat: (2018-06-01)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
per: Yael Sharon, et al.
Publicat: (2020-06-01)

Possible relationship between certolizumab pegol and arrhythmias: report of two cases
per: R. Talotta, et al.
Publicat: (2016-09-01)

Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors
per: Syuichi Koarada, et al.
Publicat: (2015-01-01)

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
per: Jeffrey R. Curtis, et al.
Publicat: (2017-12-01)